Theravance Biopharma, Inc. (TBPH) Debt to Equity Ratio
Theravance Biopharma, Inc. (TBPH) debt-to-equity ratio history and balance sheet leverage. Analyze D/E ratio in Excel with MarketXLS.
Debt to Equity Ratio Data
| Period | Debt/Equity |
|---|---|
| 2016-12-31 | 0.64 |
| 2017-12-31 | 1.94 |
| 2022-12-31 | 0.12 |
| 2023-12-31 | 0.23 |
| 2024-12-31 | 0.17 |
| 2025-12-31 | 0.10 |
Debt to equity divides total borrowings by total shareholder equity at the period end. Total borrowings are short-term debt plus long-term debt, including capital lease obligations. Non-debt liabilities such as accounts payable and deferred revenue are excluded. A period is omitted when equity is negative, because the ratio is not meaningful then.
Get Theravance Biopharma, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Debt_to_Equity_Ratio("TBPH", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | TBPH | $17.04 | +0.06% | 0.49M |
| 3 | ||||
| 4 | ||||
| 5 |